Jiangsu Vcare and Geneseeq Form Strategic Partnership for NTRK Companion Diagnostics

　　On July 2, 2024, Jiangsu Vcare and Geneseeq signed a strategic cooperation agreement in Nanjing’s Jiangbei New District. The collaboration will focus on the joint development and future commercialization of a companion diagnostic kit for the NTRK inhibitor VC004.

　　VC004, a second-generation NTRK inhibitor independently developed by Jiangsu Vcare, has demonstrated excellent in vitro and in vivo activity, favorable pharmacokinetic properties, good tolerability, and high response rates in early clinical studies. With no second-generation NTRK inhibitors currently approved in China, VC004 is poised to fill this critical gap.

　　Jiangsu Vcare: Specializes in the development of innovative drugs and advanced therapies, with deep expertise in R&D and market expansion across oncology, cardiovascular and cerebrovascular diseases, autoimmune disorders, and other therapeutic areas. The company has developed multiple clinical-stage Class I innovative drugs and clinical solutions.

　　Geneseeq: A leading Chinese precision oncology testing company, Geneseeq possesses advanced high-throughput gene sequencing technologies and extensive experience in diagnostic kit development and regulatory approval. It is the only domestic enterprise with two NGS-based innovative medical device reagent products.

　　The partnership will leverage the complementary strengths of both parties to accelerate the development and commercialization of VC004’s companion diagnostics, promote the clinical application of NTRK1/2/3 gene fusion detection, and deliver transformative benefits to cancer patients.

　　Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: “VC004, our self-developed next-generation NTRK inhibitor, is currently in a critical Phase II clinical trial in China. We are honored to partner with our ‘neighbor’ Geneseeq at this pivotal stage. Geneseeq has achieved remarkable success in translating gene sequencing technologies into clinical applications. This collaboration will integrate VC004’s research advancements with Geneseeq’s diagnostic expertise, profoundly addressing unmet clinical needs. We look forward to contributing to medical progress and human health through this partnership.”

　　Dr. Wang Xiaonan, Co-founder and Chief Technology Officer of Geneseeq, remarked: “As fellow enterprises in Nanjing’s Jiangbei New District, Geneseeq and Jiangsu Vcare have collaborated for years. Both companies prioritize innovation, driven by clinical demand, to achieve high-quality development. I am confident that this strategic alliance will accelerate the efficiency of innovative drug R&D and clinical application, ultimately providing patients with more therapeutic options and greater survival benefits.”